URGN
URGN
NASDAQ · Biotechnology

Urogen Pharma Ltd

$43.68
+0.48 (+1.11%)
As of Sep 22, 2:10 PM ET ·
Financial Highlights (FY 2026)
Revenue
111.25M
Net Income
-155,544,584
Gross Margin
88.7%
Profit Margin
-139.8%
Rev Growth
+19.5%
D/E Ratio
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 88.7% 88.7% 31.9% 31.9%
Operating Margin -113.7% -102.4% 7.4% 7.0%
Profit Margin -139.8% -132.8% 5.1% 6.0%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 111.25M 93.11M 574.93M 620.56M
Gross Profit 98.64M 82.55M 183.53M 198.10M
Operating Income -126,527,281 -95,308,464 42.60M 43.31M
Net Income -155,544,584 -117,166,158 29.33M 36.90M
Gross Margin 88.7% 88.7% 31.9% 31.9%
Operating Margin -113.7% -102.4% 7.4% 7.0%
Profit Margin -139.8% -132.8% 5.1% 6.0%
Rev Growth +19.5% +19.5% -7.8% +0.9%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 0 316.20M 293.87M
Total Equity 463.52M 437.50M
D/E Ratio 0.68 0.67
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -126,221,204 -100,360,013 65.79M 68.95M
Free Cash Flow 30.48M 44.33M